论文部分内容阅读
目的：比较不同治疗方法对绝经后骨质疏松（ＰＭＯ）患者血清白细胞介素－１，２，６（ＩＬ—１，２，６），胰岛素样生长因子Ⅱ（ＩＧＦ Ⅱ）及骨密度（ＢＭＤ）的影响，从免疫学角度探讨 ＰＭＯ的防治机制。方法：用放射免疫法测定 ７０例伴有骨疼痛的绝经后低骨量或骨质疏松患者（双阳组）的血清 ＩＬ—１，２，６和 ＩＧＦⅡ，选用单能 Ｘ线吸收测定法测定跟骨骨密度，并与 ３０例骨密度正常，无骨痛的健康绝经后妇女（双阴组）和３０例２５～３０岁健康女性青年（青年组）作对照。双阳组患者分成３组，妊马雌酮（倍美力）组（３０例），妊马雌酮、依屈膦酸二钠片（ＨＥＢＰ）联合治疗组（３０例），对照组（１０例），比较治疗前后上述细胞因子及骨密度的变化。结果：绝经后妇女均有ＩＬ—１，２，６和ＩＧＦⅡ水平上升，ＰＭＯ患者上升幅度较大。治疗后，两组患者的血清ＩＬ－１，２，６和ＩＧＦⅡ有下降趋势。妊马雌酮治疗仅能延缓骨丢失，不能逆转已经存在的低骨量。联合治疗不仅延缓骨丢失，而且使骨量增加，骨密度上升。结论：ＰＭＯ患者的免疫活性细胞释放过多的 ＩＬ—１，２，６和 ＩＧＦⅡ，参与了骨骼系统的免疫损伤。妊马雌酮和 ＨＥＢＰ联合治疗可使 ＩＬ—１，２，６和 ＩＧＦⅡ水平?
OBJECTIVE: To compare the effects of different therapies on serum levels of interleukin-1, 2, 6, insulin-like growth factor Ⅱ (IGF Ⅱ) and bone mineral density (BMD) in patients with postmenopausal osteoporosis ), From the perspective of immunology PMO prevention mechanism. Methods: The levels of IL-1, IL-6 and IGF-II in 70 postmenopausal women with low bone mass or osteoporosis (Shuangyang group) were measured by radioimmunoassay. The single-energy X-ray absorptiometry Bone mineral density, bone density and 30 normal bone mineral density pain-free healthy postmenopausal women (Shuangyin) and 30 healthy young women aged 25 to 30 (youth group) as a control. The patients in Shuangyang group were divided into three groups: 30 in pregnant women treated with estrone (30 cases), 30 cases in pregnant women treated with conjugated dipyridamole (HEBP) and 10 cases in control group ), Compared before and after treatment of the above cytokines and bone mineral density changes. Results: The levels of IL-1, 2, 6 and IGFⅡ in postmenopausal women increased, and the incidence of PMO increased more. After treatment, serum IL-1, IL-6, and IGF-II in both groups showed a decreasing trend. Pregnancy estrone treatment only delayed bone loss, can not reverse the already existing low bone mass. Combination therapy not only delays bone loss but also increases bone mass and increases bone mineral density. CONCLUSIONS: Immunocompetent cells in PMO release excessive IL-1, 2, 6 and IGF II, which are involved in the immune damage of the skeletal system. Pregnant estrone and HEBP combined treatment can IL-1,2,6 and IGF Ⅱ levels?